Chen Yanchun, Wang Qiaozhen, Wang Qing, Liu Jinmeng, Jiang Xin, Zhang Yawen, Liu Yongxin, Zhou Fenghua, Liu Huancai
Department of Histology and Embryology, School of Clinical Medicine, Weifang Medical University, Weifang, China.
Department of Human Anatomy, School of Clinical Medicine, Weifang Medical University, Weifang, China.
Front Pharmacol. 2019 Jan 24;9:1558. doi: 10.3389/fphar.2018.01558. eCollection 2018.
Osteosarcoma (OS) is a common malignant primary bone tumor. Its mechanism of development and progression is poorly understood. Currently, there is no effective therapeutic regimens available for the treatment of OS. DEAD-box helicase 5 (DDX5) is involved in oncogenic processes. This study aimed to explore the role of DDX5 in the development and progression of OS and its relationship with transcription factor 12 (TCF12), which is as an important molecule of Wnt signaling pathway. We found that the expressions of DDX5 and TCF12 protein were significantly higher in OS patients tissues and in the MG63 cells than in the corresponding normal tissues and human osteoblast cell hFOB 1.19. Overexpressions of both DDX5 and TCF12 were associated with clinicopathological features and poor prognosis of OS patients. siRNA based knockdown of DDX5 inhibited the proliferation of MG63 cells as demonstrated by an MTS assay and 5-ethynyl-2-deoxyuridine DNA proliferation detection, and promoted apoptosis of MG63 cells measured by flow cytometry. In addition, DDX5 knockdown inhibited the MG63 cell migration and invasion on transwell assays. Further experiments showed that DDX5 knockdown not only inhibited the expression of TCF12 but also decreased the mRNA and protein levels of Cyclin E1, an important regulator of G1-S phase progression, suggesting that DDX5 was required for the entry of cells into S phase. Overexpression of TCF12 reversed the cell proliferation, migration and invasion in MG63 cells induced by DDX5 knockdown accompanied by the upregulation of Cyclin E1. Additionally, we observed that DDX5 interacted with TCF12 in both OS tissues and MG63 cells by Co-immunoprecipitation assays. Taken together, our study revealed that DDX5 interacts with TCF12 and promotes the progression of OS by stimulating cell cycle progression. Our results suggest that DDX5 and TCF12 could be potential biomarkers for the diagnosis and treatment of OS.
骨肉瘤(OS)是一种常见的原发性恶性骨肿瘤。其发生和发展机制尚不清楚。目前,尚无有效的治疗方案可用于治疗骨肉瘤。DEAD盒解旋酶5(DDX5)参与致癌过程。本研究旨在探讨DDX5在骨肉瘤发生发展中的作用及其与转录因子12(TCF12)的关系,TCF12是Wnt信号通路的重要分子。我们发现,与相应的正常组织和人成骨细胞hFOB 1.19相比,骨肉瘤患者组织和MG63细胞中DDX5和TCF12蛋白的表达显著更高。DDX5和TCF12的过表达均与骨肉瘤患者的临床病理特征和不良预后相关。基于小干扰RNA(siRNA)的DDX5敲低抑制了MG63细胞的增殖,MTS检测和5-乙炔基-2'-脱氧尿苷DNA增殖检测证明了这一点,并通过流式细胞术检测促进了MG63细胞的凋亡。此外,在Transwell实验中,DDX5敲低抑制了MG63细胞的迁移和侵袭。进一步的实验表明,DDX5敲低不仅抑制了TCF12的表达,还降低了细胞周期蛋白E1(G1-S期进程的重要调节因子)的mRNA和蛋白水平,表明DDX5是细胞进入S期所必需的。TCF12的过表达逆转了DDX5敲低诱导的MG63细胞的增殖、迁移和侵袭,并伴随着细胞周期蛋白E1的上调。此外,我们通过免疫共沉淀实验观察到,在骨肉瘤组织和MG63细胞中,DDX5与TCF12相互作用。综上所述,我们的研究表明,DDX5与TCF12相互作用,并通过刺激细胞周期进程促进骨肉瘤的进展。我们的结果表明,DDX5和TCF12可能是骨肉瘤诊断和治疗的潜在生物标志物。